POS0999-HPR THE IMPACT OF THE COVID-19 PANDEMIC ON REFERRALS TO MUSCULOSKELETAL SERVICES FROM PRIMARY CARE AND SUBSEQUENT INCIDENCE OF INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASE: AN OBSERVATIONAL STUDY

Bajpai, R.; Burton, C.; Mason, K.; Bailey, J.; Frisher, M.; Jordan, K.; Mallen, C.; Welsh, V.

Abstract

Background Inflammatory rheumatic and musculoskeletal diseases (iRMDs), including rheumatoid arthritis (RA) and juveneille inflammatory arthritsi (JIA), are common and cause a high disease burden globally. Early diagnosis of iRMDs and subsequent timely access to disease modifying therapies is associated with improved health and socio-economic outcomes. However, the COVID-19 pandemic meant that the way healthcare was delivered changed abruptly as all consultations were ‘remote by default’ was widely implemented, replacing traditional ‘face-to-face’ healthcare.

Objectives To describe the impact of the COVID-19 pandemic upon referral patterns and incident diagnosis of iRMDs.

Methods Data from the Clinical Practice Research Datalink Aurum were analysed from 01/04/17 to 01/10/2021 to describe episodes of care for patients with musculoskeletal (MSK) conditions, in a primary care setting, for pre-COVID-19 (01/04/2017–31/03/2020), early-COVID-19 (01/04/2020–31/07/2021), and late-COVID-19 pandemic (01/08/2020–31/10/2021) periods. Prevalent and incident MSK consultations were determined. Referrals were matched to these consultations. Trends in referrals to MSK services and further incident diagnoses of iRMDs were described using Joinpoint regression and comparisons made between time-periods. Negative binomial regression was used to compare incident rates between time-periods: first MSK consultation to RA/JIA/iRMD diagnosis; first MSK consultation to first referral; first referral to RA/JIA/iRMD diagnosis. The number of consultations between first MSK consultation and referral/diagnosis were described. Results were adjusted for age and sex and further stratified by geographical region and deprivation.

Results The incidence of RA and JIA reduced by -13.3% (from 32.0 to 17.2 per 100,000) and -17.4% (from 1.8 to 0.97 per 1,000,000) per month respectively between January 2020 and April 2020, and then increased by 1.9% (from 17.2 to 25.2 per 100,000) and 3.7% (from 0.97 to 1.3 per 1,000,000) per month respectively between April 2020 and October 2021. The incidence of all diagnosed iRMDs was stable until October 2021. Referral incidence decreased between February 2020 and May 2020 by -16.8% (from 4.8 to 2.4 per 100) per month in patients presenting with a MSK condition. After May 2020, referrals increased significantly (16.8% per month from 2.4 to 4.5 per 100) to July 2020. Time from first MSK consultation to RA diagnosis, and referral to RA diagnosis increased in the early-pandemic period (rate ratio (RR) 1.11, 95% confidence interval (CI) 1.07-1.15; RR 1.23, 95%CI 1.17-1.30) and remained consistently higher in the late-pandemic (RR 1.13, 95%CI 1.11-1.16; RR 1.27, 95%CI 1.23-1.32) periods respectively, compared to the pre-COVID-19 period.

Conclusion Patients with underlying RA/JIA that developed during the pandemic may be yet to present, or in the process of being referred and/or diagnosed. Primary care clinicians should remain alert to this possibility and consider the use of fast-track referral pathways where indicated. It is apparent that patients developing incident episodes of inflammatory arthropathies may display a prodrome of other MSK symptoms and conditions, which alone may not warrant referral but in combination require further investigation. Commissioners should be alert to these findings to allow for the appropriate planning and commissioning of services.

• Presentation Conference Type: Poster
• Conference Name: EULAR 2023 European Congress of Rheumatology
• Conference Location: Milan, Italy
• Start Date: May 31, 2023
• End Date: Jun 3, 2023
• Deposit Date: Jun 29, 2023
• Publisher: BMJ Publishing Group
• DOI: https://doi.org/10.1136/annrheumdis-2023-eular.5004
• Keywords: General Biochemistry, Genetics and Molecular Biology; Immunology; Immunology and Allergy; Rheumatology
• Publisher URL: https://ard.bmj.com/content/82/Suppl_1/815.2